Kafrelsheikh University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Kafr El Sheikh Egypt (2006)

Organization Overview

First Clinical Trial
2015
NCT03265197
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Assistant professor of Anesthesia &ICU,Kafr El sheikh University, FACULTY OF MEDICINE | Dalia Rasheed Issa | Diaa Eldin Taha Ramadan Mohamed | eman elhosary | Faculty of Medicine Kafrelshiekh university | Faculty of Medicine , Kafrelshiekh University, Egypt. | Faculty of Science, Kafrelsheikh University, Egypt. | Kafrelsheikh University | Kafr-Elsheikh University - Faculty of Medicine | kafr elshekh university | Lecturer of Pediatrics - Kafr Elsheikh University | Lecturer of urology | neuropsychiatry department Kafrelsheikh faculty of medicine | Pediatrics department - Kafr-Elsheikh university | Pediatrics department - Kafr Elsheikh University | Pediatrics department - Kafr-Elsheikh University | Pediatrics Department- Kafr-Elsheikh University | saad elzayat

Active Ingredients

Drugs in Phase 4 Trials (10)

13-cis-retinoic Acid (8 trials)

acetylcysteine (mucomyst) (1 trial)

gamma-aminobutyric acid (1 trial)

minoxidil (loniten) (1 trial)

pentoxifylline (trental) (1 trial)

retinoic acid (3 trials)

testosterone (delatestryl) (1 trial)

ursodeoxycholic acid (1 trial)

vitamin d (2 trials)

vitamin e (1 trial)

Drugs in Phase 3 Trials (16)

acetylsalicylic acid (aspirin) (1 trial)

atomoxetine (strattera) (1 trial)

bumetanide (bumex) (1 trial)

cannabidiol (Epidiolex) (1 trial)

cis-retinoic acid (2 trials)

citicoline (3 trials)

clarithromycin (biaxin) (1 trial)

cytidine (1 trial)

isotretinoin (accutane) (3 trials)

metronidazole (flagyl) (1 trial)

mifepristone (mifeprex) (1 trial)

nitazoxanide (alinia) (1 trial)

tamoxifen (nolvadex) (3 trials)

ticagrelor (brilinta) (1 trial)

tretinoin (Retin-A) (2 trials)

ubiquinone (1 trial)

Drugs in Phase 2 Trials (9)

alpha-lipoic acid (1 trial)

chadox1 ncov-19 (1 trial)

chicroic acid (1 trial)

covid19 recombinant spike protein (1 trial)

methylene blue (proveblue) (1 trial)

minocycline (minocin) (1 trial)

pd-1 and ace2 knockout t cells (1 trial)

phenformin (1 trial)

purple grape juice (1 trial)

Drugs in Phase 1 Trials (8)

dexamethasone (2 trials)

dexmedetomidine (precedex) (1 trial)

levocarnitine (carnitor) (1 trial)

lidocaine (xylocaine) (1 trial)

ondansetron (zofran) (1 trial)

rbace2 (2 trials)

stannous protoporphyrin (1 trial)

sulfonatoporphyrin (1 trial)

Drugs in Other Trials (5)

ciprofloxacin (cipro) (1 trial)

levofloxacin (levaquin) (1 trial)

platelet rich plasma (1 trial)

tranexamic acid (cyklokapron) (1 trial)

whey protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alopecia (Phase 4)

Alopecia Areata (Phase 4)

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Cerebral Infarction (Phase 3)

Coronavirus Infections (Phase 2)

Epilepsy (Phase 4)

Hypoxia (Phase 3)

Infections (Phase 1)

Ischemia (Phase 3)

Lung Injury (Phase 1)

Poisoning (Phase 2)

Premature Birth (Phase 3)

Seizures (Phase 4)

Severe Acute Respiratory Syndrome (Phase 2)

Stroke (Phase 3)

Tinnitus (Phase 1)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 41
  • # of Trial APIs: 48